Docket No. 2024730-7034612001 (03-248)

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 1 3 200

In re the Application of:

Michael P. Wallace

Serial No.: 10/627,024

**Filed:** July 25, 2003

For: METHOD AND SYSTEM FOR

DELIVERING AN IMPLANT UTILIZING A

LUMEN REDUCING MEMBER

**Group Art Unit: 3739** 

Confirmation No.: 3679

Examiner: Not-Yet-Assigned

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR § 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. Copies of US Patents and US Patent Publications are not enclosed, pursuant to the US Patent & Trademark Office waiver of this requirement under 37 CFR § 1.98 (a)(2)(i) for patent applications filed after June 30, 2003.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

## CERTIFICATE OF MAILING

(37 C.F.R. §1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposit with the Unites States Postal Services on the date shown below with sufficient postage as "First Class Mail" to addressee in an envelope addressed to the Commissioner for Patents, Alexandria, VA 22313-1450

Signature of Per

Name of Person transmitting

Maritza D. Kidd

PA/52147635.1

### Information Disclosure Statement Filing Provision:

filed un 1.491; (	three monder § 1. or (3) be	es is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) on the filing date of the application, which is not a continued prosecution application 53(d) or (2) within three months of entry of the national stage as set forth in 37 CFR § after the mailing of a first Office action on the merits; or (4) before the mailing of a first office filing a request for continued examination under § 1.114. Thus, no fee is required.			
	However, if the undersigned is in error in this regard, Applicant respectfully requesthat the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below				
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.			
on the r § 1.311	merits, b	S is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action out before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR			
		The fee due under 37 CFR § 1.17(p) is submitted herewith.			
		A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.			
	or a No	S is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR stice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. At a 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted			
		STATEMENT UNDER 37 CFR § 1.97(e):			
	Each ite	em contained in this IDS was first cited in any communication from a foreign patent office			
in a cou	_	foreign application not more than three months prior to the filing of this IDS.			
	No item	contained in this IDS was cited in a communication from a foreign patent office in a			
counter	part for	eign application, and, to the knowledge of the person signing this statement after making			
reasona	ble inqu	iry, no item of information contained in this IDS was known to any individual designated			
in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.					

# 

David T. Burse Reg. No. 37,104

BINGHAM McCUTCHEN LLP Three Embarcadero, Suite 1800 San Francisco, CA 94111-4067 (650) 849-4400

23639
PATENT TRADEMARK OFFICE

Please type a plus sign (+) inside this box	$\rightarrow$	国	_
	6	TP	E

Approved for use through 10/31/2002. OMB 0651-0031\*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no pe are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

5.

Sheet

DEC 1 3 2004 SUPPLEMENTAL INFORMATION DISCOSU STATEMENT BY APPLICA

Complete if Known Application Number 10/627,024 Filing Date July 25, 2003 First Named Inventor Michael P. Wallace Group Art Unit 3739 **Examiner Name** Not-Yet-Assigned 30-7034612001 (03-248) Attorney Docket Number

05-15-2003

(use as many sheets as necessary) of

2003/0093106

			U.S. PATENT DOCUM	MENTS	
Examiner Initials *	Cite No.1	U.S. Patent Document	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevar Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)	of Cited Document		
	1.	2001/0029362	Sirhan et al	10-11-2001	
	2.	2002/0013599	Limon et al	01-31-2002	
	3.	2002/0095203	Thompson et al	07-18-2002	
	4.	2002/0151953	Chobotov et al	10-17-2002	

Brady et al

				FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code⁵ ( <i>if known</i> )	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T <sub>6</sub>
	6.	wo	01/56501		S & G Biotech Inc.	08-09-2001		

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examiner Initials *	Cite No. <sup>1</sup>	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T *
	7.	PCT International Search Report for PCT/US2004/016966, Applicant: Scimed Life Systems, Inc., Forms PCT/ISA/210 and 220, dated December 2, 2004 (9 pages)	
	8.	PCT Written Opinion of the International Search Authority for PCT/US2004/016966, Applicant: Scimed Life Systems, Inc., Form PCT/ISA/237, dated December 2, 2004 (7 pages)	

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.